Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9865)
All Articles published online
|
Publishing Process of This Article
|
Dec 14, 2014 (publication date) through Feb 18, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Rossi RE, Parisi I, Despott EJ, Burroughs AK, O'Beirne J, Conte D, Hamilton MI, Murray CD. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management. World J Gastroenterol 2014; 20(46): 17352-17359 [PMID: PMC4265593 DOI: 10.3748/wjg.v20.i46.17352] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i46/17352.htm |
| Number | Citing Articles |
| 1 |
Masashi Kono, Naoko Tsuji, Nobuto Ozaki, Nozomu Matsumoto, Takehisa Takaba, Naoki Okumura, Masanori Kawasaki, Takafumi Tomita, Yasuko Umehara, Satoko Taniike, Hideki Endo, Ken Ochiai, Shunji Maekura, Masatoshi Kudo. A case of psoriasis vulgaris complicated with antimitochondrial M2 antibody-positive liver dysfunction after infliximab treatment. Kanzo 2015; 56(12): 655 doi: 10.2957/kanzo.56.655
|
| 2 |
Monia E. Werlang, Michele D. Lewis, Michael J. Bartel. Tumor Necrosis Factor Alpha Inhibitor-Induced Acute Pancreatitis. ACG Case Reports Journal 2017; 4(1): e103 doi: 10.14309/crj.2017.103
|
| 3 |
Paul B. Watkins, Merrie Mosedale. Schiff's Diseases of the Liver. 2017; : 774 doi: 10.1002/9781119251316.ch28
|
| 4 |
Daniel Nisakar Meenakshi Sundaram, Samarwadee Plianwong, Remant KC, Hanne Ostergaard, Hasan Uludağ. In Vitro Cytotoxicity and Cytokine Production by Lipid-Substituted Low Molecular Weight Branched PEIs Used for Gene Delivery. Acta Biomaterialia 2022; 148: 279 doi: 10.1016/j.actbio.2022.06.030
|
| 5 |
Pingping Ren, Wei Lei, Changcheng Zhao, Zhijun Duan. HO-1-induced autophagy establishes a HO-1-p62-Nrf2 positive feedback loop to reduce gut permeability in cholestatic liver disease. Scandinavian Journal of Gastroenterology 2024; 59(8): 906 doi: 10.1080/00365521.2024.2353108
|
| 6 |
My-Linh Tran-Minh, Paula Sousa, Marianne Maillet, Matthieu Allez, Jean-Marc Gornet. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World Journal of Hepatology 2017; 9(13): 613-626 doi: 10.4254/wjh.v9.i13.613
|
| 7 |
Nada Dia, Sara Mansour, Zelal Kharaba, Bassem Malaeb, Abir Sarray El Dine, Sally Kokash, Suzanne Nasser, Souheil Hallit, Diana Malaeb. Factors associated with infertility among the Lebanese population: a cross-sectional study. International Journal of Environmental Health Research 2024; 34(2): 934 doi: 10.1080/09603123.2023.2190084
|
| 8 |
鹏飞 费. Recent Developments Related to the Toxic Side Effects of Immunosuppressive Combination Therapy. Advances in Clinical Medicine 2022; 12(08): 7292 doi: 10.12677/ACM.2022.1281053
|
| 9 |
Geert D’Haens, Marla Dubinsky, Taku Kobayashi, Peter M. Irving, Stefanie Howaldt, Juris Pokrotnieks, Kathryn Krueger, Janelle Laskowski, Xingyuan Li, Trevor Lissoos, Joe Milata, Nathan Morris, Vipin Arora, Catherine Milch, William Sandborn, Bruce E. Sands. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine 2023; 388(26): 2444 doi: 10.1056/NEJMoa2207940
|
| 10 |
Shikib Mostamand, Shauna Schroeder, Jacqueline Schenkein, Tamir Miloh. Infliximab‐Associated Immunomediated Hepatitis in Children With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition 2016; 63(1): 94 doi: 10.1097/MPG.0000000000001137
|
| 11 |
Frederick Wong, Bashaar Al Ibrahim, Joanna Walsh, Karim Qumosani. Infliximab‐induced autoimmune hepatitis requiring liver transplantation. Clinical Case Reports 2019; 7(11): 2135 doi: 10.1002/ccr3.2456
|
| 12 |
Parth Shah, Vinay Sundaram, Einar Björnsson. Biologic and Checkpoint Inhibitor‐Induced Liver Injury: A Systematic Literature Review. Hepatology Communications 2020; 4(2): 172 doi: 10.1002/hep4.1465
|
| 13 |
Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi. Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intestinal Research 2019; 17(4): 504 doi: 10.5217/ir.2019.00030
|
| 14 |
Gurfateh Singh, Ramica Sharma. Advances in Animal Experimentation and Modeling. 2022; : 195 doi: 10.1016/B978-0-323-90583-1.00007-6
|
| 15 |
Jaqueline Pereira Lana, Laís Bhering Martins, Marina Chaves de Oliveira, Zélia Menezes-Garcia, Letícia Tamie Pavia Yamada, Leda Quercia Vieira, Mauro Martins Teixeira, Adaliene Versiani Matos Ferreira. TNF and IL-18 cytokines may regulate liver fat storage under homeostasis conditions. Applied Physiology, Nutrition, and Metabolism 2016; 41(12): 1295 doi: 10.1139/apnm-2016-0265
|
| 16 |
Cagla Bali, Nejat Altintas, Ozlem Ozmete, Ibrahim Gelincik, Hakan Yabanoglu, Neslihan Tekin, Bulent Altinsoy, Bunyamin Cuneyt Turan, Anıs Aribogan. Protective Effect of Curcumin on Carbapenem-Resistant Escherichia coli–Induced Lung Injury in Rats. International Surgery 2016; 101(7-8): 304 doi: 10.9738/INTSURG-D-15-00256.1
|
| 17 |
Phan Minh Giang, Do Thi Thao, Nguyen Thi Nga, Bui Van Trung, Duong Hong Anh, Pham Hung Viet. Evaluation of the Antioxidant, Hepatoprotective, and Anti-Inflammatory Activities of Bisresorcinol Isolated from the Trunk of Heliciopsis Terminalis. Pharmaceutical Chemistry Journal 2019; 53(7): 628 doi: 10.1007/s11094-019-02051-7
|
| 18 |
S. Cazzaniga, F. Anzengruber, M. Augustin, W.H. Boehncke, L. Borradori, C. Conrad, A. Cozzio, V. Djamei, L.E. French, M. Gilliet, P. Häusermann, K. Heidemeyer, P. Itin, A.G.A. Kolios, E. Laffitte, J.‐T. Maul, C. Mainetti, L. Naldi, A.A. Navarini, S.J. Rustenbach, D. Simon, C. Sorbe, M. Streit, N. Yawalkar. Linkage between patients’ characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. Journal of the European Academy of Dermatology and Venereology 2019; 33(12): 2313 doi: 10.1111/jdv.15983
|
| 19 |
Rui Gaspar, Catarina Castelo Branco, Guilherme Macedo. Liver manifestations and complications in inflammatory bowel disease: A review. World Journal of Hepatology 2021; 13(12): 1956-1967 doi: 10.4254/wjh.v13.i12.1956
|
| 20 |
Richard Conway, John J Carey. Risk of liver disease in methotrexate treated patients. World Journal of Hepatology 2017; 9(26): 1092-1100 doi: 10.4254/wjh.v9.i26.1092
|
| 21 |
Ke-Tao Jin, Shi-Bing Wang, Xiao-Jiang Ying, Huan-Rong Lan, Jie-Qing Lv, Li-Hua Zhang, Morteza Motallebnezhad, Xiao-Zhou Mou. Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer. Immunology Letters 2020; 221: 61 doi: 10.1016/j.imlet.2020.02.008
|
| 22 |
Anwita Sinha, Shekhar Neema, Manish Manrai, Biju Vasudevan, S. Radhakrishnan. Drug-Induced Liver Injury. Indian Journal of Drugs in Dermatology 2021; 7(2): 106 doi: 10.4103/ijdd.ijdd_53_20
|
| 23 |
Deepak MW Balak, Stefano Piaserico, Ismail Kasujee. Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies. Psoriasis: Targets and Therapy 2021; : 151 doi: 10.2147/PTT.S342911
|
| 24 |
Maureen M. Kelly, Barbara S. Turner, Michael D. Kappelman, Eun Jeong Lee, Ajay S. Gulati. Implementation and Evaluation of a Standard Operating Procedure for Pediatric Infliximab Infusions. Pediatric Quality & Safety 2019; 4(1): e137 doi: 10.1097/pq9.0000000000000137
|
| 25 |
Lucy Shamberg, Haleh Vaziri. Hepatotoxicity of Inflammatory Bowel Disease Medications. Journal of Clinical Gastroenterology 2018; 52(8): 674 doi: 10.1097/MCG.0000000000001084
|
| 26 |
Jacob A. Mojeski, Robert E. Kalb. Advances in Psoriasis. 2021; : 173 doi: 10.1007/978-3-030-54859-9_14
|
| 27 |
Hao Chi Zhang, Wenyi Luo, Yinghong Wang. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. Journal for ImmunoTherapy of Cancer 2019; 7(1) doi: 10.1186/s40425-019-0532-1
|
| 28 |
Tung-Lin Lee, Tsen-Fang Tsai. Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review. Inflammation Research 2022; 71(2): 157 doi: 10.1007/s00011-021-01528-0
|
| 29 |
Celia Jacoberger-Foissac, Stephen J Blake, Jing Liu, Elizabeth McDonald, Hannah Triscott, Kyohei Nakamura, Mark J Smyth, Michele WL Teng. Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy. Journal for ImmunoTherapy of Cancer 2020; 8(2): e001687 doi: 10.1136/jitc-2020-001687
|
| 30 |
M Mosedale, PB Watkins. Drug‐induced liver injury: Advances in mechanistic understanding that will inform risk management. Clinical Pharmacology & Therapeutics 2017; 101(4): 469 doi: 10.1002/cpt.564
|
| 31 |
Elizabeth S. Aby, John R. Lake, Byron P. Vaughn. The Impact of Biologics for the Management of Inflammatory Bowel Disease on Liver Enzymes. Clinical Liver Disease 2020; 16(5): 212 doi: 10.1002/cld.1005
|
| 32 |
Ying Xiao, Don W. Powell, Xiaowei Liu, Qingjie Li. Cardiovascular manifestations of inflammatory bowel diseases and the underlying pathogenic mechanisms. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2023; 325(2): R193 doi: 10.1152/ajpregu.00300.2022
|
| 33 |
Shintaro Sagami, Kiyohiro Nishikawa, Fumika Yamada, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi. Post‐marketing analysis for biosimilar CT‐P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. Journal of Gastroenterology and Hepatology 2021; 36(8): 2091 doi: 10.1111/jgh.15399
|
| 34 |
Neeraj Chhabra, Joseph Kennedy. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. Journal of Medical Toxicology 2021; 17(4): 411 doi: 10.1007/s13181-021-00833-8
|
| 35 |
Loris Riccardo Lopetuso, Giammarco Mocci, Manuela Marzo, Francesca D’Aversa, Gian Lodovico Rapaccini, Luisa Guidi, Alessandro Armuzzi, Antonio Gasbarrini, Alfredo Papa. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver. International Journal of Molecular Sciences 2018; 19(8): 2199 doi: 10.3390/ijms19082199
|
| 36 |
Juergen Braun, Uta Kiltz, Michael Sarholz, Frank Heldmann, Andrea Regel, Xenofon Baraliakos. Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. Expert Review of Clinical Immunology 2015; 11(8): 935 doi: 10.1586/1744666X.2015.1052795
|
| 37 |
Stephanie Dorta-Estremera, Renee L. Chin, Gloria Sierra, Courtney Nicholas, Ananta V. Yanamandra, Sita M.K. Nookala, Guojun Yang, Shail Singh, Michael A. Curran, K. Jagannadha Sastry. Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers. Cancer Research 2018; 78(18): 5327 doi: 10.1158/0008-5472.CAN-18-0892
|
| 38 |
Richard Conway, Candice Low, Robert J. Coughlan, Martin J. O’Donnell, John J. Carey. Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials. Seminars in Arthritis and Rheumatism 2015; 45(2): 156 doi: 10.1016/j.semarthrit.2015.05.003
|
| 39 |
Sarah Raevens, Michael B. Fallon. Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models. Hepatology 2018; 68(5): 2016 doi: 10.1002/hep.30079
|
| 40 |
Cynthia Morvillo, Katherine Vinci, Lauren Hedenschoug, Leah Mancini, Carrie Mize, Kayce Tugg, Steven Stein. Risks and Safety of Advanced Therapies and Biologics in Inflammatory Bowel Disease. Gastroenterology Nursing 2020; 43(4): E159 doi: 10.1097/SGA.0000000000000523
|
| 41 |
Nejat Altintas, Mustafa Erboga, Cevat Aktas, Bulent Bilir, Murat Aydin, Aysun Sengul, Zehra Ates, Birol Topcu, Ahmet Gurel. Protective Effect of Infliximab, a Tumor Necrosis Factor-Alfa Inhibitor, on Bleomycin-Induced Lung Fibrosis in Rats. Inflammation 2016; 39(1): 65 doi: 10.1007/s10753-015-0224-z
|
| 42 |
Iosune Baraibar, Ignacio Melero, Mariano Ponz-Sarvise, Eduardo Castanon. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. Drug Safety 2019; 42(2): 281 doi: 10.1007/s40264-018-0774-8
|
| 43 |
Agazi Gebreselassie, Farshad Aduli, Charles D. Howell. Rheumatologic Diseases and the Liver. Clinics in Liver Disease 2019; 23(2): 247 doi: 10.1016/j.cld.2018.12.007
|
| 44 |
Joshua B. French, Maurizio Bonacini, Marwan Ghabril, David Foureau, Herbert L. Bonkovsky. Hepatotoxicity Associated with the Use of Anti-TNF-α Agents. Drug Safety 2016; 39(3): 199 doi: 10.1007/s40264-015-0366-9
|
| 45 |
Aliki I. Venetsanopoulou, Paraskevi V. Voulgari, Alexandros A. Drosos. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis. Expert Review of Clinical Immunology 2022; 18(5): 485 doi: 10.1080/1744666X.2022.2064275
|
| 46 |
Salvatore Magrì, Luchino Chessa, Mauro Demurtas, Francesco Cabras, Giammarco Mocci. Review article: safety of new biologic agents for inflammatory bowel disease in the liver. European Journal of Gastroenterology & Hepatology 2021; 33(5): 623 doi: 10.1097/MEG.0000000000002076
|
| 47 |
Y T Lim, S Robinson, M M Tang. Liver disease among patients with psoriasis: the Malaysian Psoriasis Registry. Clinical and Experimental Dermatology 2023; 48(5): 476 doi: 10.1093/ced/llad013
|